Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Tenax Therapeutics to host conference call » 15:55
01/21/21
01/21
15:55
01/21/21
15:55
TENX

Tenax Therapeutics

$2.57 /

+0.14 (+5.76%)

Management holds a…

Management holds a conference call to review the previously announced acquisition of PH Precision Med will be held on January 21 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
TENX Tenax Therapeutics
$2.57 /

+0.14 (+5.76%)

TENX Tenax Therapeutics
$2.57 /

+0.14 (+5.76%)

12/29/20 H.C. Wainwright
Tenax Therapeutics initiated with a Buy at H.C. Wainwright
Conference/Events
Tenax Therapeutics to host conference call » 04:55
01/21/21
01/21
04:55
01/21/21
04:55
TENX

Tenax Therapeutics

$2.43 /

+0.05 (+2.10%)

Management holds a…

Management holds a conference call to review the previously announced acquisition of PH Precision Med will be held on January 21 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
TENX Tenax Therapeutics
$2.43 /

+0.05 (+2.10%)

TENX Tenax Therapeutics
$2.43 /

+0.05 (+2.10%)

12/29/20 H.C. Wainwright
Tenax Therapeutics initiated with a Buy at H.C. Wainwright
Conference/Events
Tenax Therapeutics to host conference call » 10:46
01/20/21
01/20
10:46
01/20/21
10:46
TENX

Tenax Therapeutics

$2.30 /

-0.08 (-3.36%)

Management holds a…

Management holds a conference call to review the previously announced acquisition of PH Precision Med will be held on January 21 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
TENX Tenax Therapeutics
$2.30 /

-0.08 (-3.36%)

TENX Tenax Therapeutics
$2.30 /

-0.08 (-3.36%)

12/29/20 H.C. Wainwright
Tenax Therapeutics initiated with a Buy at H.C. Wainwright
Hot Stocks
Tenax Therapeutics announces 'transformative' acquisition of PH Precision Med » 07:49
01/19/21
01/19
07:49
01/19/21
07:49
TENX

Tenax Therapeutics

$1.77 /

-0.01 (-0.56%)

Tenax Therapeutics…

Tenax Therapeutics announced the acquisition of PH Precision Med, PHPM, a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension, PAH. The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax's pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase inhibitor that transformed the treatment of cancer by blocking the underlying pathways resulting in long lasting remissions. Subsequent preclinical and clinical studies in PAH indicate that imatinib may provide antiproliferative and disease-modifying effects in PAH patients through its ability to inhibit several growth factors including platelet-derived growth factor. PDGF regulates vascular smooth muscle cell proliferation in PAH and is thought to be associated with the disease progression. Multiple clinical studies of imatinib in PAH patients provide convincing evidence that imatinib can provide impressive improvements in exercise capacity and hemodynamics in patients with advanced PAH. The strong efficacy results from these trials, combined with imatinib's antiproliferative mechanism action, have raised the possibility that imatinib may work by modifying the underlying PAH disease process. Pursuant to the acquisition, Tenax's clincial development plan includes advancing a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway. "The acquisition of PHPM immediately expands Tenax's pipeline to include a second de-risked Phase 3 ready candidate with the potential to be the first disease modifying treatment of pulmonary arterial hypertension," said Anthony DiTonno, Chief Executive Officer of Tenax. "The previous clinical trial designs led to high dropout rates and raised questions related to safety and tolerability, which limited further development of imatinib in PAH. We believe that PHPM's innovative clinical development plan, which includes a novel formulation that mitigates the side effects without diminishing the bioavailability, has the potential to yield positive clinical outcomes in a single pivotal Phase 3 trial requisite for regulatory approval." Stuart Rich, MD, co-founder of PHDM, has been appointed Chief Medical Officer of Tenax Therapeutics. Dr. Rich current

ShowHide Related Items >><<
TENX Tenax Therapeutics
$1.77 /

-0.01 (-0.56%)

12/29/20 H.C. Wainwright
Tenax Therapeutics initiated with a Buy at H.C. Wainwright
Initiation
Tenax Therapeutics initiated with a Buy at H.C. Wainwright » 06:06
12/29/20
12/29
06:06
12/29/20
06:06
TENX

Tenax Therapeutics

$1.08 /

-0.03 (-2.70%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Vernon Bernardino initiated coverage of Tenax Therapeutics with a Buy rating and $5 price target. The analyst sees potential for levosimendan to be the first approved treatment for pulmonary hypertension from heart failure with preserved ejection fraction. He believes positive results from the HELP study bode well for Phase 3.

ShowHide Related Items >><<
Over a quarter ago
Syndicate
Tenax Therapeutics files to sell 15M shares of common stock for holders  16:33
08/20/20
08/20
16:33
08/20/20
16:33
TENX

Tenax Therapeutics

$1.56 /

+0.09 (+6.12%)

 
ShowHide Related Items >><<
TENX Tenax Therapeutics
$1.56 /

+0.09 (+6.12%)

Syndicate
Tenax Therapeutics announces $8M registered direct offering » 19:55
07/06/20
07/06
19:55
07/06/20
19:55
TENX

Tenax Therapeutics

$0.91 /

+0.0028 (+0.31%)

Tenax Therapeutics…

Tenax Therapeutics announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 2,523,611 shares of its common stock at a purchase price of $1.02780 per share and pre-funded warrants to purchase up to 652,313 shares of common stock, at a purchase price of $1.02770 per pre-funded warrant, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

ShowHide Related Items >><<
TENX Tenax Therapeutics
$0.91 /

+0.0028 (+0.31%)

Hot Stocks
Tenax Therapeutics regains compliance with Nasdaq minimum bid price requirement » 08:32
06/03/20
06/03
08:32
06/03/20
08:32
TENX

Tenax Therapeutics

$1.63 /

+0.19 (+13.19%)

Tenax Therapeutics…

Tenax Therapeutics announced that it received notice from The Nasdaq Stock Market on June 2, indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and the matter is now closed.

ShowHide Related Items >><<
TENX Tenax Therapeutics
$1.63 /

+0.19 (+13.19%)

Hot Stocks
Tenax Therapeutics announces results from levosimendan study » 07:46
06/02/20
06/02
07:46
06/02/20
07:46
TENX

Tenax Therapeutics

$1.44 /

+ (+0.00%)

Tenax Therapeutics…

Tenax Therapeutics announced Phase 2 results for levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction, or PH-HFpEF. In this 37 patient study, the primary efficacy analysis, pulmonary capillary wedge pressure, or PCWP, during exercise did not demonstrate a statistically significant reduction from baseline. Levosimendan did demonstrate a statistically significant reduction in PCWP compared to baseline and placebo when the measurements at rest, with legs up and on exercise were combined. Levosimendan also demonstrated a statistically significant improvement in 6-minute walk distance as compared to placebo. Hemodynamic measurements were made at rest, after leg raise on a supine bicycle and during exercise. Levosimendan demonstrated a statistically significant reduction in PCWP compared to baseline and placebo when the measurements at rest, with legs up and on exercise were combined. While there was no significant change in PCWP during exercise, patients receiving levosimendan had reductions from baseline at Week 6 in PCWP, pulmonary artery pressure and right atrial pressure that were significant when patients were "at rest" and/or with their "legs raised". The clinical efficacy was confirmed by a statistically significant improvement in 6-minute walk distance of 29 meters. The 6-minute walk distance was a secondary endpoint in the trial and is a validated and accepted endpoint used in many pulmonary hypertension registration trials. Levosimendan was given in once-weekly home infusions for 6 weeks. The incidence of AEs or SAEs between the control and treated groups were similar. In addition, there were no arrhythmias observed, atrial or ventricular, when comparing baseline electrocardiographic monitoring with 72-hour monitoring after 5 weeks of treatment. The company plans to present the full study results at future medical meetings and will submit a full manuscript of the trial results to a peer-reviewed journal.

ShowHide Related Items >><<
TENX Tenax Therapeutics
$1.44 /

+ (+0.00%)

Hot Stocks
Tenax Therapeutics: last patient completes final visit in Phase 2 HELP study » 08:39
04/09/20
04/09
08:39
04/09/20
08:39
TENX

Tenax Therapeutics

$0.62 /

-0.0473 (-7.09%)

Tenax Therapeutics…

Tenax Therapeutics announced that the last patient has completed their final visit in the Company's Phase 2 clinical trial of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study is also known as the HELP Study (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF). The 36-subject clinical trial began enrollment in late March 2019 and patients were randomized in 10 hospitals across the U.S. Trial finalization leading to data lock and top-line data readout has now begun. Top-line data readout remains on track for late June 2020. PH-HFpEF represents an area of very high unmet medical need. PH-HFpEF patients suffer from increased mortality as well as a reduced quality of life. No approved or effective therapies currently exist to treat the many patients who suffer with PH-HFpEF.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.